Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Phreesia, Inc. PHR

Healthcare — Health Information Services
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years ,
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
28.77
Total sells
2.12
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — 2 — — — — — —
Sell 7 — 2 14 — 3 5 1 1 3 — —
Insider Ownership
8.17%

Capital & Financial Ratios

Market Cap
638.09
Revenue
507.79
Net Income
10.45
Free Cash Flow
67.52
Net Debt
77.69
Current Ratio
1.76
Debt/Equity
0.41
P/E ratio
59.06
P/S ratio
1.22
P/B ratio
1.67
Past 5Y EPS Growth
16.05%
This Y EPS Growth
642.81%
Next Y EPS Growth
116.65%
Next 5Y EPS Growth
164.07%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2026 ‡‡‡
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2016 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2024 2025 2026 Q'26
Cash 87.52 84.22 73.83 72.95
Receivables 64.86 73.62 154.63 134.28
Inventory — — — —
Other 28.07 29.18 33.00 26.75
195.68 203.29 279.84 253.50
2024 2025 2026 Q'26
Payables 8.48 5.62 11.48 12.24
ST’ Debt — — 38.06 29.74
Other 33.95 29.18 33.70 27.48
110.12 114.02 183.24 143.84
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Apr Jul Oct Jan Year
’26 130.94 129.46 — —
—
’26 115.94 117.26 120.33 127.07
480.59
’25 101.22 102.12 106.80 109.68
419.81
’24 83.85 85.83 91.62 95.01
356.30
’23 63.35 67.87 73.10 76.59
280.91
’22 48.29 51.01 55.92 58.02
213.23
’21 33.40 35.01 38.46 41.81
148.68
in millions of $

Operating Cash Flow

Apr Jul Oct Jan Year
’26 23.92 18.33 — —
—
’26 14.85 14.84 15.47 33.66
78.81
’25 (0.72) 11.06 5.79 16.26
32.38
’24 (13.66) (9.33) (6.31) (3.08)
(32.38)
’23 (33.63) (19.84) (20.75) (15.90)
(90.12)
’22 (5.47) (6.73) (24.53) (37.98)
(74.71)
’21 1.90 (2.42) (0.67) 4.08
2.89
in millions of $

Free Cash Flow

Apr Jul Oct Jan Year
’26 16.37 13.82 — —
—
’26 7.46 9.63 8.80 28.53
54.42
’25 (6.17) 3.66 1.60 9.20
8.29
’24 (19.74) (15.17) (11.62) (10.94)
(57.47)
’23 (40.66) (25.69) (27.48) (22.50)
(116.33)
’22 (12.37) (9.88) (39.03) (44.23)
(105.51)
’21 (1.17) (6.74) (4.37) (3.39)
(15.68)
in millions of $

EPS

Apr Jul Oct Jan Year
’26 0.05 0.03 — —
—
’26 (0.07) 0.01 0.07 0.02
0.04
’25 (0.35) (0.31) (0.25) (0.11)
(1.02)
’24 (0.70) (0.68) (0.58) (0.56)
(2.51)
’23 (0.99) (0.89) (0.76) (0.72)
(3.36)
’22 (0.24) (0.48) (0.71) (0.90)
(2.37)
’21 (0.16) (0.17) (0.17) (0.18)
(0.69)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2
1
Buy
2
3
Hold
4
5
Sell
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.19 12.05 17.07 15.41 7.77 — — —
Low Price
— — ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 43.47 40.00 29.16 32.76 17.60 — — —
High Price
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,701 1,546 1,438 2,082 1,789 — — —
Employees
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.13 0.18 0.25 0.20 0.27 — — —
Revenue/Emp
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 213.23 280.91 356.30 419.81 480.59 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 61.83% 61.10% 65.19% 67.86% 67.93% — — —
Gross Margin
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (117.98) (175.66) (135.34) (55.81) (8.94) ‡‡‡‡‡ — —
EBT
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (55.33%) (62.53%) (37.99%) (13.29%) (1.86%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (118.16) (176.15) (136.88) (58.53) 2.31 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 23.80 27.31 30.86 29.94 35.00 — — —
Depreciation
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.27 5.36 6.53 7.29 8.05 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ (2.37) (3.36) (2.51) (1.02) 0.04 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.50) (1.72) (0.59) 0.56 1.32 — — —
Cash Flow/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.62) (0.50) (0.46) (0.42) (0.41) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.11) (2.22) (1.05) 0.14 0.91 — — —
Free CF/Sh
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.36 5.49 4.61 4.60 5.64 — — —
Book Value/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 49.89 52.44 54.56 57.59 59.74 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 440.33 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
— ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.30 7.00 3.90 3.90 1.64 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.73 6.83 5.53 6.19 2.34 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.89 6.40 3.69 3.74 1.85 ‡‡‡‡ ‡‡‡‡ ‡‡‡
EV/Sales
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (11.91) (15.46) (22.89) 189.37 16.37 — — —
EV/FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (74.71) (90.12) (32.38) 32.38 78.81 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (30.80) (26.20) (25.10) (24.09) (24.40) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (105.51) (116.33) (57.47) 8.29 54.42 ‡‡‡‡‡ — —
FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 317.92 183.40 85.57 89.26 96.60 — — —
Working Cap'
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.53 8.83 5.40 8.15 175.50 — — —
Total Debt
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (299.29) (167.85) (82.12) (76.07) 101.67 — — —
Net Debt
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 417.28 287.82 251.45 264.81 337.21 — — —
Sh' Equity
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (28.78%) (40.75%) (36.98%) (15.43%) 0.44% ‡‡‡‡‡ — —
ROA
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (61.88%) (91.98%) (50.37%) (19.24%) (0.94%) — — —
ROIC
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (34.72%) (49.96%) (50.77%) (22.67%) 0.77% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Phreesia, Inc. (PHR), a leader in patient intake software, has delivered impressive revenue growth—from $80 million in 2018 to $356 million in 2024—amid healthcare’s digital shift, with projections reaching $480 million by 2026. Gross margins have climbed to 65%, free cash flow turned positive at $83 million last year, and the balance sheet shines with debt slashed 97% to just $5 million, yielding a net cash position. Yet profitability remains nascent, with analysts forecasting a swing to positive EPS in 2025, while the stock trades near lows, 60% below consensus targets—raising questions of deep value or persistent execution hurdles.

This turnaround hinges on narrowing losses (down 57% in 2024) and steady revenue per share growth to $7.97 by 2026, bolstered by partnerships like Epic and expansions into life sciences. Valuation metrics scream bargain—forward EV/sales at 1.3x—versus peers, with ROA flipping positive. However, post-IPO dilution, volatile stock action tied to margin swings, and recent insider selling (over $11 million, led by executives) signal caution, potentially capping rallies amid healthcare reimbursement risks.

While tailwinds like AI-driven care and a fragmented $4 trillion market position Phreesia for 15% CAGR through 2028, downside risks from competition, regulatory pressures, and headcount volatility loom large. Fundamentals point to substantial upside if profitability sticks, but prudent investors will monitor Q1 2026 results and insider flows before committing.

Read full commentary →

Phreesia, Inc. (PHR) Latest News

News by impact score

Fine-tune

17 Sep

3 , 4:58 PM
Analysts split on Phreesia (PHR) with improving margins offset by fading growth visibility. Mixed signals on margins and growth create noticeable but limited effects on investor views and performance.

14 Sep

3 , 6:45 AM
Phreesia’s ProviderConnect Audiences are now available in the DeepIntent Audience Marketplace. Availability expands Phreesia audience distribution channels with moderate effects on reach and revenue.

13 Sep

3 , 5:53 AM
Phreesia achieves profit turnaround but faces revenue risks from cash-strapped clients. Cash-strapped clients may pressure revenue and slow growth despite recent profit gains.

9 Sep

3 transcript www.fool.com, 5:29 PM
Phreesia (PHR) held its Q2 2027 earnings call covering quarterly financial results and business outlook. Quarterly earnings call supplies updated financial metrics and guidance that can shift near-term valuation.

3 Sep

4 transcript , 1:00 AM
Phreesia Inc reported record EBITDA margin for Q2 2027 during its earnings call along with strategic updates. Record EBITDA margin reflects improved profitability that can materially strengthen future performance and investor outlook.

3 www.fool.com, 7:41 PM
Phreesia shares declined after the company reported quarterly results that fell short of expectations and issued cautious forward guidance. Quarterly results and guidance directly influence near-term valuation and investor sentiment but rarely alter long-term fundamentals.

3 transcript app.moby.co, 8:30 AM
Phreesia, Inc. held its Q2 2027 earnings call, outlining quarterly financial results, operational updates, and forward guidance. Quarterly earnings calls deliver financial metrics and guidance that shape near-term investor views without guaranteeing structural shifts.

2 Sep

3 www.marketbeat.com, 6:03 PM
Phreesia released Q2 earnings call highlights covering financial results, operational updates and forward guidance. Q2 earnings and guidance updates typically affect near-term stock movement without altering long-term company trajectory.

3 , 5:10 PM
Phreesia (PHR) posted Q2 earnings and revenues below analyst estimates. Q2 earnings and revenue shortfall may pressure near-term stock price and investor sentiment.

3 , 4:03 PM
Phreesia, Inc. released financial results for its second quarter of fiscal 2027. Quarterly results provide financial performance data that can influence investor sentiment and valuation.

21 Jul

3 , 6:50 AM
MediFind launches AI-powered chatbot to help patients find and book suitable healthcare providers. MediFind AI chatbot launch represents product innovation for Phreesia with moderately noticeable effects on operations and positioning.

10 Jun

3 Simply Wall St., 8:21 AM
Phreesia reports strong earnings of good quality. Positive earnings quality assessment can moderately support investor views on financial performance.

4 Jun

3 Insider Monkey, 9:19 AM
Phreesia (PHR) exhibits strong upside potential driven by favorable market positioning and growth prospects. Optimistic view on PHR upside may lift near-term investor sentiment and share price without altering core operations.

28 May

4 transcript GuruFocus.com, 1:00 AM
Phreesia Inc posted strong revenue growth alongside positive net results in its Q1 2027 earnings call. Strong Q1 revenue growth and positive net metrics indicate material improvement in financial trajectory and investor sentiment.

27 May

4 transcript www.fool.com, 7:50 PM
Phreesia (PHR) Q1 2027 earnings transcript details quarterly financial performance and executive discussions. Earnings results and outlook directly shape near-term valuation and investor positioning for PHR.

3 app.moby.co, 8:17 PM
Phreesia, Inc. conducted its Q1 2027 earnings call. Quarterly earnings calls deliver financial updates that can shift near-term investor views without guaranteeing major strategic changes.

3 transcript www.marketbeat.com, 7:04 PM
Phreesia Inc. reported Q1 financial results and provided operational updates during its earnings call. Quarterly earnings and guidance influence near-term investor sentiment and valuation.

3 Zacks, 5:30 PM
Phreesia reported Q1 earnings and revenues exceeding analyst estimates. Q1 earnings and revenue beats signal improved financial results likely to lift near-term sentiment.

3 Business Wire, 4:03 PM
Phreesia, Inc. (PHR) announced financial results for its first quarter of fiscal 2027. Quarterly earnings releases deliver routine financial updates that can moderately shift short-term investor sentiment without major strategic shifts.

20 May

3 www.fool.com, 8:00 PM
Phreesia shares plunged sharply after the company posted quarterly results that missed estimates on both revenue and earnings while issuing weaker forward guidance, triggering broad investor selling. Missed estimates and reduced guidance create short-term pressure on valuation and sentiment without fundamentally changing the company's market position.

19 May

3 Simply Wall St., 8:10 AM
Phreesia faces a shifting market narrative driven by slower ad growth and rising competitive pressures that may weigh on its performance outlook. Slower ad growth combined with tougher competition is likely to pressure Phreesia's revenue trajectory and competitive standing.

8 May

4 Insider Monkey, 8:29 AM
Phreesia (PHR) shares slid after the company cut its financial guidance, disappointing investors amid ongoing challenges. Guidance cut directly signals weaker expected financial performance, eroding investor confidence and stock value significantly.

2 Apr

4 Simply Wall St., 7:21 AM
Phreesia (PHR) stock plunged 25.5% despite reporting its first full-year profit, as investors reacted negatively to lower-than-expected revenue guidance for 2027. Stock dropped 25.5% on disappointing 2027 revenue guidance despite first full-year profit, signaling potential shifts in financial trajectory and investor sentiment.

3 www.marketbeat.com, 8:55 AM
Phreesia hit bottom in Q1 with weakening revenue and rising losses, but signs point to rebound via new client wins, backlog growth, and efficiency gains, though timing remains uncertain. Q1 marked the bottom with revenue decline and losses, but rebound signals from client additions and backlog suggest moderate financial recovery potential.

1 Apr

4 Barrons.com, 4:18 AM
Phreesia's growth guidance disappointed investors, leading analysts to withdraw their buy recommendation amid concerns over future performance. Disappointing growth guidance and withdrawn recommendation threaten revenue trajectory and sharply erode investor confidence.

31 Mar

4 Investing.com, 6:13 AM
Phreesia (PHR) shares sank 26% after the company issued a substantial cut to its financial outlook, prompting multiple Wall Street downgrades. Substantial outlook cut triggered 26% stock plunge and analyst downgrades, likely reshaping investor sentiment and near-term performance.

3 www.fool.com, 11:00 AM
Phreesia shares plunged over 20% after Q2 revenue missed estimates at $106.6 million, losses widened to $0.42 per share, and full-year guidance was cut to $425-431 million from $440-446 million amid softer patient volumes. Earnings miss and guidance cut will notably pressure financial performance and investor sentiment short-term but core operations remain intact.

30 Mar

4 GuruFocus.com, 11:00 PM
Phreesia Inc. (PHR) reported record revenue growth and strategic initiatives in its Q4 2026 earnings call highlights. Record revenue growth and strategic initiatives indicate major positive shifts in financial performance and competitive positioning.

4 app.moby.co, 8:15 PM
Phreesia, Inc. (PHR) Q4 2026 earnings call summary details financial results, operational highlights, and forward-looking guidance. Q4 earnings call summaries disclose critical financial metrics and strategic guidance that significantly influence market performance and investor sentiment.

4 www.marketbeat.com, 8:06 PM
Phreesia, Inc. (PHR) Q4 earnings call highlights key financial results, revenue growth, profitability improvements, and optimistic 2025 guidance amid strong patient visit volumes and platform expansions. Q4 earnings highlights detail strong financial performance and forward guidance signaling significant positive trajectory shifts for Phreesia.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us